GlassScriptPhysician profile
Kelly L Carson
NPI 1801859327
$8,113.30
in general payments reported to CMS, 2019-2025
37 companies · $1,818 in 2025
The $1,818 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $722 · 2020: $319 · 2021: $730 · 2022: $1,239 · 2023: $1,545 · 2024: $1,740 · 2025: $1,818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,084 · Education: $19.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,084.36 |
| Education | $19.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,043.34 | 2019-2025 | Skyrizi, Rinvoq, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $995.30 | 2019-2025 | Entyvio, Gattex |
| Genzyme Corporation | $656.18 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $566.49 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Pfizer INC. | $537.80 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $410.47 | 2022-2025 | Dupixent |
| Celgene Corporation | $393.36 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $327.49 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $228.38 | 2019-2023 | Stelara |
| Organon LLC | $217.94 | 2023-2025 | Renflexis, Hadlima |
| Intercept Pharmaceuticals, INC. | $167.05 | 2023-2024 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $148.56 | 2024-2025 | Iqirvo, Bylvay |
| Ironwood Pharmaceuticals, INC | $145.38 | 2019-2023 | Linzess |
| Lilly USA, LLC | $139.63 | 2023-2024 | Omvoh |
| Merck Sharp & Dohme LLC | $122.74 | 2022-2024 | Dificid, Zinplava |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $116.65 | 2024-2025 | Vegzelma, Zymfentra |
| Qol Medical, LLC | $113.19 | 2020-2024 | Sucraid, Sucraid |
| Ferring Pharmaceuticals INC. | $109.63 | 2019-2022 | |
| Allergan, INC. | $84.75 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $78.36 | 2024-2025 | Voquezna |
| Daiichi Sankyo INC. | $63.74 | 2022-2023 | Injectafer |
| Braintree Laboratories, INC. | $61.75 | 2019-2022 | |
| Medtronic, INC. | $59.25 | 2023-2025 | Interstim, Pillcam |
| Blueprint Medicines Corporation | $43.28 | 2023 | |
| Aimmune Therapeutics, INC. | $38.51 | 2024 | |
| Stryker Corporation | $29.35 | 2025 | Pedi-Pom |
| Redhill Biopharma INC. | $26.26 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.04 | 2023 | Cyltezo |
| Romark Laboratories, Lc | $21.98 | 2019 | |
| Gilead Sciences, INC. | $21.70 | 2025 | |
| Vivus LLC | $20.43 | 2022 | |
| Nestle Healthcare Nutrition INC. | $18.63 | 2020 | |
| Ardelyx, INC. | $18.44 | 2025 | Ibsrela |
| Novo Nordisk INC | $17.96 | 2025 | Wegovy |
| Olympus America INC. | $16.89 | 2025 | Endoclot Air Compressor |
| Micro-Tech Endoscopy USA, INC. | $13.34 | 2023 | Lesionhunter |
| Fresenius Kabi USA, LLC | $13.06 | 2023 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Carson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.